Video

Dr. Weitzel on the Identification of Li-Fraumeni Syndrome

Jeffery Weitzel, MD, discusses the identification of ​Li-Fraumeni syndrome.

Jeffery Weitzel, MD, director, Division of Clinical Cancer Genomics, Department of Population Sciences; director, Cancer Screening & Prevention Programs Network; director, Cancer Genomics Education Program; professor of medicine, Department of Medical Oncology & Therapeutics Research and Department of Population Sciences, City of Hope, discusses the identification of ​Li-Fraumeni syndrome (LFS).

Li-Fraumeni syndrome ​is a rare inherited familial predisposition to a multitude of cancers, says Weitzel. ​The syndrome is caused by a mutation in the TP53 gene.

Notably, this syndrome is associated with a severe phenotype ​and high prevalence in children and young adults under the age of 20, ​Weitzel explains. In children, LFS tends to cause brain tumors, adrenocortical carcinoma​s, and soft tissue or bone sarcomas.

Conversely, in young adults, LFS is associated with early onset breast cancer​; however, for patients over 30 years of age, this syndrome is less problematic, Weitzel concludes.

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc